RAPT Therapeutics, Inc. RAPT
Set alert
As of Mar 6, 9:30 AM ET
- YTD
- +71.26%
- 1 year
- +547.38%
- Open
- 58.01
- Prev close
- 58.01
- Mkt cap
- 1.61B
- Vol
- 10.85M
- Avg vol
- 4.25M
- EPS
- -11.06
- P/E
- -44.46
- Div yield
- 0.00%
More statistics
- Low
- 58.01
- High
- 58.01
- Beta
- 0.44
- Inst. own
- 110.57%
- Dividend
- 0.00
3M chart
Events in this range
- Jan 20, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
- Jan 20, 2026Downgrade: TD Cowen · Buy → Hold
- Jan 20, 2026Downgrade: LifeSci Capital · Outperform → Market Perform
- Jan 20, 2026Downgrade: Wells Fargo · Overweight → Equal-Weight
- Jan 21, 2026Downgrade: Leerink Partners · Outperform → Market Perform
- Jan 21, 2026Downgrade: Barclays · Overweight → Equal-Weight
- Mar 5, 2026Earnings: -9.12; estimate -0.82293; surprise -1008.24%
Signals (13)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Feb 6, 2026 | 8 months ago |
| RSI: Overbought | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 15, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 9, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Jan 2, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
Key statistics
- Market cap
- 1.61B
- Enterprise value
- 1.57B
- Trailing P/E
- -44.46
- PEG ratio
- -0.67
- Price / sales
- 0.00
- Price / book
- 10.29
- Beta
- 0.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -22.27%
Analyst view
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 5, 2026 | Dec 30, 2025 | -0.82293 | -9.12 | -8.30 | -1,008.24% |
| Nov 6, 2025 | Sep 30, 2025 | -0.88 | -0.65 | +0.23 | +26.14% |
| Aug 7, 2025 | Jun 30, 2025 | -0.61 | -0.65 | -0.04 | -6.56% |
| May 8, 2025 | Mar 31, 2025 | -2.48 | -0.64 | +1.84 | +74.19% |
| Mar 6, 2025 | Dec 31, 2024 | -3.60 | -9.12 | -5.52 | -153.33% |
| Nov 12, 2024 | Sep 30, 2024 | -0.56 | -3.76 | -3.20 | -571.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 21, 2026 | Barclays | down | Overweight | Equal-Weight |
| Jan 21, 2026 | Leerink Partners | down | Outperform | Market Perform |
| Jan 20, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jan 20, 2026 | LifeSci Capital | down | Outperform | Market Perform |
| Jan 20, 2026 | TD Cowen | down | Buy | Hold |
| Jan 20, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. These treatments are aimed at addressing critical unmet medical needs for patients battling oncology and inflammatory diseases. Its primary drug candidate for inflammation, RPT193, functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. This compound works by selectively preventing type 2 T helper cells from migrating into inflamed tissues. In the oncology pipeline, FLX475 stands as the company's leading candidate, also an oral small molecule CCR4 antagonist. This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy both as a standalone treatment and in combination with pembrolizumab for individuals with advanced cancer. RAPT Therapeutics is also engaged in the development of a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Founded in 2015, the company initially operated as FLX Bio, Inc. before rebranding as RAPT Therapeutics, Inc. in May 2019. Its corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 67
- Website
- rapt.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on RAPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRAUNSTEIN SCOTT N. | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| DOMBKOWSKI ASHLEY L | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| GIORDANO MICHAEL F | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| GRAY MARY ANN | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| KOZICK LINDA | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| LYONS-WILLIAMS LORI | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 10.08% | 2,794,000 | 162.11M | Dec 30, 2025 |
| TCG Crossover Management, LLC | 9.32% | 2,582,408 | 149.83M | Dec 30, 2025 |
| FCPM III Services B.V. | 6.62% | 1,833,333 | 106.37M | Dec 30, 2025 |
| Orbimed Advisors LLC. | 5.93% | 1,642,891 | 95.32M | Dec 30, 2025 |
| RTW Investments LP | 5.91% | 1,637,165 | 94.99M | Dec 30, 2025 |
| Foresite Capital Management VI LLC | 5.64% | 1,562,500 | 90.66M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.98% | 827,036 | 47.98M | Dec 30, 2025 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.98% | 547,644 | 31.77M | Dec 30, 2025 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.99% | 273,226 | 15.85M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.75% | 207,602 | 12.05M | Dec 30, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.48% | 131,880 | 7.65M | Dec 30, 2025 |
| -Fidelity SAI Merger Arbitrage Fund | 0.45% | 125,000 | 7.25M | Jan 30, 2026 |